eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2008
vol. 25
 
Share:
Share:
more
 
 
abstract:

Original paper
The use of biological agents in the treatment of psoriasis

Agnieszka Gerkowicz
,
Grażyna Chodorowska
,
Jakub Chodorowski

Post Dermatol Alergol 2008; XXV, 6: 283–288
Online publish date: 2009/01/12
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Nail involvement occurs in 10-50% of patients with psoriasis vulgaris. Nail psoriasis tends to be refractory to the treatment, and becomes an important issue due to the psychological and therapeutic problems. Therefore research is done to find alternative therapeutic methods for patients who did not achieve any improvement after conventional therapies (both local and systemic). Recently there have been a few publications that announced the possibilities of using new immunomodulating drugs in the treatment of nail psoriasis. Recent studies have proved the efficacy and safety of infliximab and alefacept as therapeutic agents for nail psoriasis. The clinical trials which evaluate the therapeutic benefits of using etanercept, efalizumab and adalimumab in the treatment of nail psoriasis are still ongoing. This article is a review of literature regarding the efficacy and safety of these modern biological agents in the treatment of nail psoriasis.
keywords:

nail psoriasis, biological therapy, treatment

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe